In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased.
Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases …

Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …

Fibroblast activation protein (FAP) has become an attractive target for diagnosis and
therapy, and a series of FAP inhibitor (FAPI)–based radiotracers has been developed and …

Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology
because these proteins are overexpressed on the cell membranes of different human …

Since the first introduction of sodium iodide I-131 for use with thyroid patients almost 80
years ago, more than 50 radiopharmaceuticals have reached the markets for a wide range …

To date, limited data are available concerning peptide receptor radionuclide therapy (PRRT)
of grade 3 (G3) neuroendocrine neoplasms (NENs) with a Ki-67 proliferation index of …

Introduction Radiopharmaceuticals that target cancer-associated fibroblasts (CAFs) have
become an increasingly attractive strategy for cancer theranostics. Recently, a series of …

Cancer remains a major cause of death globally. Given its relapsing and fatal features,
curing cancer seems to be something hardly possible for the majority of patients. In view of …

ABSTRACT Introduction: 177Lutetium-[DOTA°, Tyr3] octreotate (177Lu-DOTATATE) is a
type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 …

In recent years, advancement in genetics has profoundly helped to gain a more
comprehensive molecular, pathogenic, and prognostic picture of pheochromocytomas and …